Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts

Progress in Biophysics and Molecular Biology

Volumn 121, Issue 1, 2016, Pages 3-10

  Hondeghem, Luc M ^a  

^a HPC nv   (Belgium)

Author keywords

Action potential duration; Dispersion and cardiac wavelength; Instability; QT interval; Reverse use dependence; Torsade de Pointes; Triangulation; Ventricular fibrillation

Indexed keywords

ACTION POTENTIAL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECT; FEMALE; HEART; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE FIBRILLATION; LEPORIDAE; PATHOPHYSIOLOGY; PERFUSION; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; FEMALE; HEART; HEART CONDUCTION SYSTEM; PERFUSION; RABBITS; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 84962687133     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2016.03.004     Document Type: Review

References (45)

1. Altman D.G., Gardner M.J. Regression and correlation. Statistics with Confidence 2000, 71-73. B.M.J. Books, Blackwell, (Chapter 8). second ed. D. Altman, D. Machin, T. Bryant, S. Gardner (Eds.).
2. Bode F., Kilborn M., Karasik P., Franz M.R. The repolarization-excitability relationship in the human right atrium is unaffected by cycle length, recording site and prior arrhythmias. J. Am. Coll. Cardiol. 2001, 37:920-925.
3. Burdon-Sanderson J., Page F.J.M. On the time-relations of the excitatory process in the ventricle of the heart of the frog. J. Physiol. 1882, 2:385-412.
4. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., Richard S. Prediction of the risk of torsade de pointes using the model of isolated canine Purkinje fibres. Br. J. Pharmacol. 2005, 144:376-385.
5. Claro J.C., Candia R., Rada G., Baraona F., Larrondo F., Letelier L.M. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst. Rev. 2015, 8:12.
6. Dumotier B.M., Deurinck M., Yang Y., Traebert M., Suter W. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis. Pharmacol. Ther. 2008, 119:152-159.
7. Eslami V., Safi M., Taherkhani M., Adibi A., Movahed M.R. Evaluation of QT, QT dispersion, and T-wave peak to end time changes after primary percutaneous coronary intervention in patients presenting with acute ST-elevation myocardial infarction. J. Invasive Cardiol. 2013, 25:232-234.
8. Guo D., Zhao X., Wu Y., Liu T., Kowey P.R., Yan G.X. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J. Cardiovasc. Electrophysiol. 2007, 18:196-203.
9. a properties. J. Cardiovasc. Electrophysiol. 1994, 5:711-721.
10. Hondeghem L.M. Relative contributions of TRIaD and QT to proarrhythmia. J. Cardiovasc. Electrophysiol. 2007, 18:655-657.
11. Hondeghem L.M., De Clerck F. Short patent Lives Jeopardize drug and patient safety. J. Cardiovasc. Pharmacol. 2007, 50:353-357.
12. Hondeghem L.M., Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol. 2003, 41:14-24.
13. Hondeghem L.M., Katzung B.G. Time and voltage dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim. Biophys. Acta 1977, 472:373-398.
14. Hondeghem L., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation 2001, 103:2004-2013.
15. Hondeghem L.M., Lu H.R., van Rossem K., De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J. Cardiovasc. Electrophysiol. 2003, 14:287-294.
16. Hondeghem L.M., Dujardin K., Hoffmann P., Dumotier B., De Clerck F. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J. Cardiovasc. Pharmacol. 2011, 57:589-597.
17. ICH e-14: Harmonised tripartite guideline The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs 2005, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
18. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349:667-674.
19. Kay G.N., Plumb V.J., Arciniegas J.G., Henthorn R.W., Waldo A.L. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Am. Cardiol. 1983, 2:806-817.
20. Lande G., Maison-Blanche P., Fayn J., Ghadanfar M., Coumel P., Funck-Brentano C. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin. Pharmacol. Ther. 1998, 64:312-321.
21. Langendorff O. Untersuchungen am überlebenden Säugetierherzen. Investigation of the living mammalian heart. Pflügers Arch. 1895, 61:291-332.
22. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. Nonclinical proarrhythmia models: predicting torsades de pointes. J. Pharmacol. Toxicol. 2005, 52:46-59.
23. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., Valentin J.P. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br. J.Pharmacol. 2006, 149:845-860.
24. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. In vitro models of proarrhythmia. Br. J. Pharmacol. 2008, 154:1516-1522.
25. Lewis T., Drury A.N. Revised views of refractory period in relation to drugs reputed to pro-long it and in relation to circus movement. Heart 1926, 13:95-100.
26. Lipicky R.J. A viewpoint on drugs that prolong the QTc interval. Am. J. Cardiol. 1993, 72:53B-54B.
27. s blockade at high heart rate in Guinea pig and rabbit implications for Arrhythmgenesis in humans. Circulation 2001, 104:951-956.
28. Lu H.R., Remeysn P., Somers K., Saels A., De Clerck F. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J. Cardiovasc. Electrophysiol. 2001, 12:538-545.
29. Lu H.R., Vlaminckx E., Van Ammel K., De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. Eur. J. Pharmacol. 2002, 452:183-192.
30. Martin R.L., Su Z., Limberis J.T., Palmatier J.D., Cowart M.D., Cox B.F., Gintant G.A. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J. Cardiovasc. Pharmacol. 2006, 48:199-206.
31. Milberg P., Eckardt L., Bruns H.J., Biertz J., Ramtin S., Reinsch N., Fleischer D., Kirchhof P., Fabritz L., Breithardt G., Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J. Pharmacol. Exp. Ther. 2002, 303:218-225.
32. Milberg P., Hilker E., Ramtin S., Cakir Y., Stypmann J., Engelen M.A., Mönnig G., Osada N., Breithardt G., Haverkamp W., Eckardt L. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J. Cardiovasc. Electrophysiol. 2007, 18:647-654.
33. Naito M., Michelson E.L., Kaplinsky E., Dreifus L.S., David D., Blenko T.M. Role of early cycle ventricular extrasystoles in initiation of ventricular tachycardia and fibrillation: evaluation of the R on T phenomenon during acute ischemia in a canine model. Am. J. Cardiol. 1982, 49:317-322.
34. N.I.H., revised Guide for the Care and Use of Laboratory Animals 1996, N.I.H. Publication No. 85-23.
35. Patel C., Yan G., Antzelevitch C. Short QT syndrome: from bench to bedside. Circ. Arrhythm. Electrophysiol. 2010, 3:401-408.
36. Roden D.M. Current status of class III antiarrhythmic drug therapy. Am. J. Cardiol. 1993, 72:50B-52B.
37. Roten L., Derval N., Maury P., Mahida S., Pascale P., Leenhardt A., Jesel L., Deisenhofer I., Kautzner J., Probst V., Rollin A., Ruidavets J.B., Ferrières J., Sacher F., Heg D., Scherr D., Komatsu Y., Daly M., Denis A., Shah A., Hocini M., Jaïs P., Haïssaguerre M. Benign versus malignant inferolateral early repolarization: focus on the T wave. Heart Rhythm 2016, 13(4):894-902.
38. + current: differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 1990, 96:195-215.
39. Segerson N.M., Litwin S.E., Daccarett M., Wall T.S., Hamdan M.H., Lux R.L. Scatter in repolarization timing predicts clinical events in post-myocardial infarction patients. Heart Rhythm 2008, 5:208-214.
40. Shah R.R., Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005, 2:758-772.
41. Shimizu W., Antzelevitch C., Suyama K., Kurita T., Taguchi A., Aihara N., Takaki H., Sunagawa K., Kamakura S. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J. Cardiovasc. Electrophysiol. 2000, 11:1320-1329.
42. Valentin J.P., Hoffmann P., De Clerck F., Hammond T.G., Hondeghem L.M. Review of the predictive value of the Langendorff heart model (SCREENIT system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. 2004, 49:171-181.
43. Varro A., Lathrop D.A., Hester S.B., Nanasi P.P., Papp G.Y. Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes. Basic Res. Cardiol. 1993, 88:93-102.
44. Viitasalo M., Paavonen K.J., Swan H., Kontula K., Toivonen L. Effects of epinephrine on right ventricular monophasic action potentials in the LQT1 versus LQT2 form of long QT syndrome: preferential enhancement of "triangulation" in LQT1. Pacing Clin. Electrophysiol. 2005, 28:219-227.
45. Viskin S., Havakuk O., Antzelevitch C., Rosso R. Malignant early repolarization: it's the t-wave, stupid. . .. Heart Rhythm 2016, http://dx.doi.org/10.1016/j.hrthm.2015.12.017.